NT-proBNP blood test measured on the day of (pre-) vascular surgery
Time frame · 4 days
NT-proBNP blood test measured on the day of (pre-) vascular surgery
Status
Recruiting
Phase
Not applicable
Enrollment
200
Locations
1
Results
Not posted
Publications
7
Study summary
The team is investigating whether N-terminal pro B-type natriuretic peptide (NT-proBNP) and other cardiac markers are useful for predicting outcomes for patients undergoing vascular surgery. By measuring NT-proBNP before and after surgery, the investigators may be able to determine which patients are at risk of an adverse outcome, such as a heart attack or death.
Almost 1 in 5 patients who have elective major vascular surgery experience death or a myocardial infarction (MI) at 18 months post-surgery. Research has shown that peri-operative interventions may improve outcomes for high-risk patients. Cardiac bio-markers may be used to identify these high-risk patients, in particular pre- and post-operative NT-proBNP. Mahla found that by comparing surgery outcomes with NT-proBNP concentrations peri-operatively, high-risk patients could be identified and subsequent therapeutic decisions could be made to minimise adverse outcomes. Van Kimmenade evaluated patients with acute heart failure and found that galectin-3 (Gal-3) was the best predictor of 60-day mortality compared with NT-proBNP and apelin (another cardiac marker), whereas NT-proBNP was the most useful for diagnosing HF. The authors also found that the combination of both markers (Gal-3 and NT-proBNP) have an even higher predictive value for outcome. The predictive role of troponin I (cTnI) has been observed in a paper by Bursi et al. (2005) where patients undergoing elective major vascular surgery were stratified using the American College of Cardiology/American Heart Association (ACC/AHA) guidelines and followed up over a period of 24 months. Patients in every group with an elevated post-operative cTnI (≥100ng/L) were at greater risk of either MI or death. The successful identification of high-risk patients can go on to have interventional risk-reducing pharmacological, therapeutic, diagnostic, or observational measures. Prevention of cardiovascular events, particular for an aging population, can have positive impact on both the patient and society as a whole as it may result in patients maintaining their independence, avoiding major illness, avoiding nursing home care and living longer.
Interventions
No intervention details reported.
Timeline
First posted
Jul 10, 2019
Study start
Sep 5, 2019
Primary completion
Sep 5, 2029
Study completion
Sep 5, 2029
Results posted
Not reported
Registry updated
Jun 8, 2026
Outcomes
NT-proBNP blood test measured on the day of (pre-) vascular surgery
Time frame · 4 days
NT-proBNP blood test measured on the day of (pre-) vascular surgery
NT-proBNP blood test measured on the day 4 after (post-) vascular surgery
Time frame · 4 days
NT-proBNP blood test measured on the day 4 after (post-) vascular surgery
Change in NT-proBNP peri-operatively
Time frame · 4 days
Change in NT-proBNP peri-operatively
Pre-, post-, and peri-operative troponin I
Time frame · 4 days
Pre-, post-, and peri-operative troponin I
Pre-, post-, and peri-operative galectin-3
Time frame · 4 days
Pre-, post-, and peri-operative galectin-3
Pre-, post-, and peri-operative CRP
Time frame · 4 days
Pre-, post-, and peri-operative CRP
Pre-, post-, and peri-operative creatinine
Time frame · 4 days
Pre-, post-, and peri-operative creatinine
Eligibility
Inclusion Criteria: * Patients who are equal to or over 18 years old * Patients scheduled to undergo elective surgery for the following procedures: * Infrainguinal arterial reconstruction * Aortic aneurysm * Aorto-bifemoral bypass / or aortic endarterectomy * Femoro-popliteal bypass * Femoro-distal bypass * Femoral endarterectomy * Femoro-femoral crossover * Axillo-femoral bypass * Elective carotid surgery * Patients having either general or regional anaesthesia for their surgery Exclusion Criteria:- * Patients undergoing emergency surgery * Those who are unable or unwilling to give informed consent * Patients with unstable coronary syndromes (acute or recent MI with evidence of important ischemic risk by clinical symptoms or stress testing or unstable or severe angina pectoris) * Patients with decompensated heart failure (new onset shortness of breath and rales together with echocardiographic evidence of cardiac dysfunction or deterioration of chronic heart failure despite heart failure therapy) * Patients with chronic atrial fibrillation
Study locations
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
Norfolk & Norwich University Hospitals NHS Foundation Trust
Norwich, Norfolk, United Kingdom
Publications
Related trials
Universidade do Porto · Heart Failure
Not applicable
Recruiting
160
2026-07
Boston Medical Center · Congestive Heart Failure · Volume Overload
Not applicable
Not yet recruiting
200
2026-06
China National Center for Cardiovascular Diseases · AKI - Acute Kidney Injury · Cardiac Surgical Procedures
Phase 4
Not yet recruiting
694
2026-06
Cambridge University Hospitals NHS Foundation Trust · Heart Failure
Not applicable
Recruiting
250
2026-05
Chulalongkorn University · Acute Kidney Failure Stage 3
Not applicable
Completed
100
2026-05
Ottawa Heart Institute Research Corporation · Chronic Right-Sided Heart Failure · Pulmonary Arterial Hypertension
Phase 4
Completed
15
2026-05
Novartis · Chronic Heart Failure and Reduced Ejection Fraction (HFrEF)
Not applicable
Completed
236
2026-04
The First Affiliated Hospital of Guangzhou Medical University · Lung Transplantation
Not applicable
Completed
80
2026-04
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.